基于COVID-19“痰栓”本质的治疗思考  

Concerns about the Pharmacotherapeutics of COVID-19 Based on the Essence of“Sputum Emboli”

作　　者：冯缤 陈正贤[2] 金龙伟 郑志华 冯起校 FENG Bin;CHEN Zhengxian;JIN Longwei;ZHENG Zhihua;FENG Qixiao(The First Affiliated Hospital of Jinan University,Guangzhou,Guangdong 510630,China;The Sixth Affiliated Hospital,Sun Yat-sen University,Guangzhou,Guangdong 510630,China;Hospital of Integrated Traditional Chinese and Western Medicine,Southern Medical University,Guangzhou,Guangdong 510220,China;Guangdong Pharmaceutical Association,Guangzhou,Guangdong 510030,China)

机构地区：[1]暨南大学第一附属医院,广东广州510630 [2]中山大学附属第六医院,广东广州510630 [3]南方医科大学中西医结合医院,广东广州510220 [4]广东省药学会,广东广州510030

出　　处：《今日药学》2020年第4期220-224,共5页Pharmacy Today

摘　　要：目的根据新型冠状病毒肺炎(COVID-19)病理特征,探讨"痰栓"的本质、黏液溶解剂治疗的可行性及其药物选择。方法综述COVID-19病理特征等相关文献,结合笔者的工作体会,总结出COVID-19黏液溶解剂治疗方法。结果"痰栓"并不是脓痰;"痰栓"中的黏液成分中,均含有大量的酸性黏蛋白。黏液溶解剂氨溴索盐酸盐与乙酰半胱氨酸对COVID-19具有重要的治疗作用。结论对COVID-19病人应常规使用黏液溶解剂进行治疗。OBJECTIVE Based on the pathological characteristics of COVID-19,the nature of"sputum emboli",the feasibility of treatment with mucolytic agents,and drug selection were discussed.METHODS By referring to the related literature of COVID-19,and combining the authors working experience,the treatment method of COVID-19 mucolytic agent was summarized.RESULTS"sputum emboli"was not purulent.The mucus component in the"sputum emboli"contains a large amount of acidic mucin.ambroxol hydrochloride and acetylcysteine had important therapeutic effects on COVID-19.CONCLUSION The patients with COVID-19 should be treated routinely with mucolytic agents.

关 键 词：痰栓 黏液溶解剂 急性呼吸窘迫综合征 新型冠状病毒肺炎 

分 类 号：R22[医药卫生—中医基础理论]